← Eichor
Study identifier: NCT04457544 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Spontaneous Coronary Artery Dissection National Swiss Registry

Condition: Spontaneous Coronary Artery Dissection  ·  Sponsor: Dr. Sophie Degrauwe

PhaseN/A
Planned participants1000
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Spontaneous coronary artery dissection (SCAD), is an underdiagnosed pathology, affecting predominantly young women without traditional cardiovascular risk factors and is associated with major adverse outcomes including myocardial infarction, cardiac arrest, or death. Timely diagnosis of SCAD as well as clinical follow-up are of the essence in this pathology associated with major cardiac adverse outcomes. Despite recent improvements in diagnosis and recognition of the importance of SCAD, it remains poorly studied and understood. In this context, we designed the SwissSCAD registry, a large, observational, prospective, cohort study, to describe the natural history of SCAD, its outcomes and its treatments.

This description comes directly from the study's public registry record.

Talk to the study team

Sophie Degrauwe, Dr  ·  +41795530294  ·  sophie.degrauwe@hcuge.ch

Veronique Menoni, PhD  ·  +41795530917  ·  Veronique.Menoni@hcuge.ch

Always discuss trial participation with your own doctor first.

Locations (1)

Geneva University HospitalsGeneva, SwitzerlandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04457544